CVS Health ( NYSE: CVS) on Thursday announced plans to discontinue operations in the individual health insurance business, ...

CVS’s stock surges toward a one-year high after profit and revenue beat expectations, amid strength in the pharmacy business, ...

Wegovy and Zepbound are part of a wave of obesity medications known as GLP-1 receptor agonists that have soared in popularity ...

CVS Health said it will significantly expand access to Novo Nordisk's blockbuster weight loss drug Wegovy for patients ...

Approximately 9,000 CVS locations will begin selling Wegovy for $499 per month to customers who pay cash out of pocket.

Merck's $3.9B SpringWorks deal, Hims & Hers' Wegovy partnership, CVS exiting Obamacare, and FDA updates on key drugs.

Aetna is once again retreating from the Affordable Care Act market, while its parent company notched a deal with Danish ...

CVS Health topped Q1 estimates with $94.59 billion in revenue and raised 2025 EPS outlook to $6.00–$6.20 amid strong Medicare ...

Starting July 1, Wegovy will become the preferred GLP-1 for obesity treatment on CVS Caremark’s largest commercial template ...

Effective July 1, 2025, CVS Caremark will place Wegovy injection 2.4 mg as preferred on its commercial template formularies.

Starting July 1, CVS said Wegovy will be the preferred weight-loss ... while membership increased by 1.1%. For health services, which include CVS Caremark, revenue increased 7.9% to $43.46 billion ...